# 2025 Business Performance Review & 2026 Growth Strategy
> Explore a strategic growth agenda featuring ₹5.02 Cr revenue delivery, pharma partnership scaling, and new leadership frameworks for 2026.

Tags: performance-review, business-growth, strategic-partnerships, revenue-ownership, leadership-plan, pharma-marketing, growth-agenda
## 2025 Performance Review & 2026 Growth Agenda
* Focus: Revenue ownership, strategic account depth, and scalable growth.

## 2025 Executive Summary
* Delivered ₹5.02 Cr total revenue.
* 27 strategic deals (20 New, 7 Renewals).
* Established ₹20.57 Cr opportunity funnel with 126 proposals and 380 meetings.
* Onboarded 13 strategic brands across Vaccines and Derma.

## Operational Activity 2025
* Conducted 380 total meetings.
* Engagement peaks noted in February (49) and July (38).

## Key Financial Metrics & Outcomes
* Total Revenue: ₹5.02 Cr.
* Opportunity Funnel: ₹20.57 Cr.
* Meeting Efficiency: 39% self-scheduled.
* Conversion Rigor: 126 Proposals.

## Strategic Transformation
* Transitioned from vendor to long-term partner.
* Secured Enterprise MSAs with Bayer and Danone.
* Executed 500+ omnichannel touchpoints.

## 2026 Priority Accounts & Focus
* GSK: Augmentin, Calpol.
* Cipla: Respiratory leadership (Foracort, Duolin).
* USV: Diabetes and Cardiology.
* Bayer: CV, Women’s Health.
* Danone: Nutricia and clinical nutrition.

## Innovation: Therapy Intelligence Hub™
* Shifting to an 'always-on' therapy authority model.
* Provides continuous clinical influence and measurable outcomes for pharma partners.

## 2026 Growth Ambition
* Target: ₹10 Cr revenue (approx. 2x increase).
* Focus on multi-brand enterprise partnerships.

## Leadership & Team Scaling
* Preparation for senior leadership and team expansion.
* Plan to onboard the first team member in Q1 2026.
---
This presentation was created with [Bobr AI](https://bobr.ai) — an AI presentation generator.